Private Trust Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Private Trust Company’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-161	Closed	-$13.4K	–	2551
2024 Q4	$13.4K	Hold	161	–	–	﹤0.01%	1645
2024 Q3	$11.8K	Hold	161	–	–	﹤0.01%	1661
2024 Q2	$11K	Sell	161 -19	-11%	-$1.32K	﹤0.01%	1649
2024 Q1	$12.5K	Buy	180 +14	+8%	+$962	﹤0.01%	1591
2023 Q4	$11.9K	Hold	166	–	–	﹤0.01%	1586
2023 Q3	$8.65K	Hold	166	–	–	﹤0.01%	1648
2023 Q2	$10.5K	Sell	166 -5	-3%	-$312	﹤0.01%	1604
2023 Q1	$9.26K	Sell	171 -12	-7%	-$580	﹤0.01%	1610
2022 Q4	$10K	Sell	183 -28	-13%	-$1.4K	﹤0.01%	1572
2022 Q3	$10K	Buy	211 +11	+6%	+$575	﹤0.01%	1471
2022 Q2	$11K	Buy	+200	New	+$11.3K	﹤0.01%	1476

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Private Trust Company's ITCI Position: Q1 2025 in Review

Private Trust Company sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 161 shares — an estimated $13.4K sold.

Private Trust Company first reported a position in ITCI in Q2 2022 and held it in 11 quarters. The position peaked at $13.4K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Private Trust Company reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Private Trust Company sold 161 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $13.4K.
Private Trust Company first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 11 quarters.
Private Trust Company's Intra-Cellular Therapies Inc. position peaked at $13.4K in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Private Trust Company's 13F filing for Q1 2025, filed 28 Apr 2025.